| DB ID | MyCo_3649 |
| Title | Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection |
| Year | 1994 |
| PMID | 8106769 |
| Fungal Diseases involved | Pulmonary aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | None |
| Site of Infection | None |
| Opportunistic invasive | None |
| Sample type | Body fluid |
| Sample source | Bronchoalveolar lavage fluid (BALF) |
| Host Group | Animal |
| Host Common name | Rabbit |
| Host Scientific name | Oryctolagus cuniculus |
| Biomarker Name | D-Mannitol |
| Biomarker Full Name | D-Mannitol |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | USA |
| Cohort | New Zealand White rabbits weighing 2.0-3.0 kg (Hazelton, Rockville, MD) were used for all studies. |
| Cohort No. | None |
| Age Group | None |
| P Value | None |
| Sensitivity | None |
| Specificity | None |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Pulmonary aspergillosis has emerged as an important cause of infectious morbidity and mortality in patients with profound granulocytopenia and corticosteroid-induced phagocyte dysfunction. Early diagnosis is a critical fac- tor for successful therapeutic outcome but is difficult and often not achieved until refractory pulmonary aspergillosis is deeply established. Currently, desoxycholate amphotericin B is the treatment of choice for pulmonary aspergillosis in granulocytopenic patients; however, its usefulness is limited by acute and chronic toxicities. Antifungal therapy is further compromised by the profound level of granulocyto- penia in these patients. Despite aggressive antifungal therapy, the mortality from pulmonary aspergillosis remains high, underscoring the urgent need for diagnostic and therapeutic advances for this infection. |
| Technique | Gas chromatography |
| Analysis Method | Gas Chromatography−Mass Spectrometry (GC-MS) Analysis |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | Gas-liquid chromatography (GLC)/mass spectrometry (MS) Analysis, Latex agglutination immuno-assay |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
